Florida Mesothelioma Fact Sheet
While mesothelioma is a problem in all states, the specific incident rate for Florida is 1 / 100,000. This is below the average rate of 1.1 / 100,000. Click on the tabs below to find mesothelioma and asbestos research in FL, recent FL mesothelioma-related court cases, mesothelioma specialists in FL and potential asbestos hotspots in Florida.
Florida Mesothelioma Info
By clicking on the above tabs, you will find information on mesothelioma specific to the state of Florida
Florida Research and Clinical Trials
This is a partial list of scientific or medical grants in your state for research into mesothelioma and related illnesses.
Florida Doctors and Hospitals
This is a partial list of hospitals and physicians that reportedly treat mesothelioma patients in your state.
Florida Cases
This is a partial list of relevant court cases on mesothelioma in your state.
Disclaimer: Inclusion on this directory does not constitute endorsement by Cancer Monthly, Inc. All physicians who appear in this section do so based on their own expression of interest in the fields of mesothelioma treatment. Cancer Monthly, Inc. has not verified the competence, professional credentials, business practices or validity of the expressed interests of these physicians. Cancer Monthly makes no recommendation of any physician on this list and makes no suggestion that any such physician will cure or prevent any disease. Those consulting a physician on this list should approach the consultation exactly as they would with any other unknown physician.
This is a partial list of scientific or medical grants in your state for research into mesothelioma and related illnesses.
Florida Doctors and Hospitals
This is a partial list of hospitals and physicians that reportedly treat mesothelioma patients in your state.
Florida Cases
This is a partial list of relevant court cases on mesothelioma in your state.
Disclaimer: Inclusion on this directory does not constitute endorsement by Cancer Monthly, Inc. All physicians who appear in this section do so based on their own expression of interest in the fields of mesothelioma treatment. Cancer Monthly, Inc. has not verified the competence, professional credentials, business practices or validity of the expressed interests of these physicians. Cancer Monthly makes no recommendation of any physician on this list and makes no suggestion that any such physician will cure or prevent any disease. Those consulting a physician on this list should approach the consultation exactly as they would with any other unknown physician.
Owens-Corning Fiberglas Corp. v. Ballard
No. 92,963 , SUPREME COURT OF FLORIDA, August 26, 1999, Decided
No. 92,963 , SUPREME COURT OF FLORIDA, August 26, 1999, Decided
Williams v. Am. Optical Corp.
Nos. 4D07-143, 4D07-144, 4D07-145, 4D07-146, 4D07-147, 4D07-148, 4D07-149, 4D07-150, 4D07-151, 4D07-153, 4D07-154, 4D07-405, And 4D07-407., COURT OF APPEAL OF FLORIDA, FOURTH DISTRICT, May 28, 2008, Decided
Nos. 4D07-143, 4D07-144, 4D07-145, 4D07-146, 4D07-147, 4D07-148, 4D07-149, 4D07-150, 4D07-151, 4D07-153, 4D07-154, 4D07-405, And 4D07-407., COURT OF APPEAL OF FLORIDA, FOURTH DISTRICT, May 28, 2008, Decided
Fernandez v. Union Carbide Corp.
CASE NO. 3D03-3142 , COURT OF APPEAL OF FLORIDA, THIRD DISTRICT, September 6, 2006, Opinion Filed
CASE NO. 3D03-3142 , COURT OF APPEAL OF FLORIDA, THIRD DISTRICT, September 6, 2006, Opinion Filed
Hospitals and Cancer Centers
Physicians
Lary A. Robinson, M.D.
H. Lee Moffitt Cancer Center & Research Institute
At The University of South Florida
12902 Magnolia Dr.
Tampa, FL 33612
Physicians
Lary A. Robinson, M.D.
H. Lee Moffitt Cancer Center & Research Institute
At The University of South Florida
12902 Magnolia Dr.
Tampa, FL 33612
| City | Site |
|
Wometko Vending | |
| Anaheim |
Disneyland |
| Destin |
Sky Host Imm |
| Foley |
Buckeye Cellulose Corp Paper Mill |
| Fort Pierce |
US Naval Base |
| Hialeah |
American Mica Products |
| Jacksonville |
Steam Turbine Unit |
| Jacksonville |
US Naval Station |
| Key West |
Naval Shipyard |
| Live Oak |
Florida Power Plant |
| Mayport |
Mayport Naval Shipyard US Naval Station |
| Miami |
BF Goodrich Dade Shipyard Miami Naval Shipyard |
| Orlando |
Disney World Women's Memorial Hospital |
| Panama City |
International Paper Company Nuclear Power-Foster Wheeler Tyndall AFB Wainwright Shipyard |
| Pascagoula |
Chevron Oil Refinery |
| Pensacola |
Champion Paper Mill Chemstrand Nylon Plant Monsanto Chemical |
| St. Joe |
St Joe Paper |
| Tallahassee |
Tallahassee Memorial Hospital |
| Tampa |
Gulf Steamship Lines Portland Cement Building |
| Tampa |
United Heating & Air |
| Tampa |
Women's Memorial Hospital |
| Tampa Bay |
Tampa Terrace Hotel Texaco Station US Fosswick |
Research
Sachdeva, Nandip S. Biodegradable Nanocapules For Delivery Of Monensin As Potentiator Of Immunotoxins
Grant: 2S06GM008111-250048
Grant: 2S06GM008111-250048
Abstract: Immunotoxins have been used as tumor-specific cytotoxic agents by various
investigators in academics and industry. One of the major limitations has
been their low potency in vivo. Potentiators like monensin have been used
with great success in vitro but their lipophillic nature has precluded
their use in vivo. Liposomes (with long circulating times) containing
monensin are being currently investigated as potentiators of immunotoxins
in vitro and in vivo. The main objective of this research is to prepare
nanocapsules of a carboxylic ionophore, monensin which can bypass the
reticuloendothelial system (to be termed as 'stealth nanocapsules'). These
nanocapsules will be used as potentiators of the anti My9 immunotoxin
conjugate (IT) which is presently in Phase III clinical trials. The
nanocapsules will be fully characterized for their entrapment efficiency,
size, stability and pharmacokinetics profile. Stealth monensin
nanocapsules will be incubated with the IT conjugate and different human
tumor cell lines to see the in vitro potentiation. All in vitro
qualitative and quantitative parameters of monensin nanocapsules will be
compared to 'stealth' monensin liposomes. Monensin nanocapsules will be
further tested for their potentiation of IT in vivo using human tumor
xenografts in a i.p/i.v. and i.v./i.v. tumor model (using nude mice) with
stealth monensin liposomes as controls. Two different human tumors, H-
mesothelioma and HL-60 cells will be used as tumor xenografts. The results
emanating from the above studies will allow us to decide what drug delivery
system to use, polymer based or lipid based.
The completion of the above studies will allow us to choose one formulation
for Phase I studies to be used in combination with the IT conjugate as a
potentiator.
Tags: Drug Delivery System, Drug Design /synthesis /production, Drug Screening /evaluation, Immunotoxicity, Microcapsule, Monensin, Neoplasm /cancer Chemotherapy, Neoplastic Cell Antineoplastic, Pharmacokinetics Athymic Mouse, Calorimetry, Computer Processing Of Laboratory Data, High Performance Liquid Chromatography, Human Tissue, Laboratory Mouse, Scanning Electron Microscopy, Statistics /biometry, Tissue /cell Culture
Tags: Drug Delivery System, Drug Design /synthesis /production, Drug Screening /evaluation, Immunotoxicity, Microcapsule, Monensin, Neoplasm /cancer Chemotherapy, Neoplastic Cell Antineoplastic, Pharmacokinetics Athymic Mouse, Calorimetry, Computer Processing Of Laboratory Data, High Performance Liquid Chromatography, Human Tissue, Laboratory Mouse, Scanning Electron Microscopy, Statistics /biometry, Tissue /cell Culture
- Followup Grant: 5S06GM008111-260048
- Followup Grant: 3S06GM008111-26S10048
- Followup Grant: 5S06GM008111-270048
- Followup Grant: 3S06GM008111-27S10048
- Followup Grant: 5S06GM008111-280048
Clinical Trials
Active, not recruiting Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma
Condition: Malignant Mesothelioma
Intervention: Drug: dasatinib; Other: immunoenzyme technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
More Information
Intervention: Drug: dasatinib; Other: immunoenzyme technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
More Information
Condition: Malignant Mesothelioma
Intervention: Drug: carboplatin; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium
More Information
Intervention: Drug: carboplatin; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium
More Information
Condition: Malignant Mesothelioma
Intervention: Drug: pazopanib hydrochloride; Other: laboratory biomarker analysis
More Information
Intervention: Drug: pazopanib hydrochloride; Other: laboratory biomarker analysis
More Information
Condition: Malignant Mesothelioma
Intervention: Drug: epirubicin hydrochloride; Drug: gemcitabine hydrochloride
More Information
Intervention: Drug: epirubicin hydrochloride; Drug: gemcitabine hydrochloride
More Information
Condition: Lung Cancer; Malignant Mesothelioma; Pancreatic Cancer; Sarcoma
Intervention: Drug: L-alanosine
More Information
Intervention: Drug: L-alanosine
More Information
Condition: Ovarian; Melanoma; Renal; Prostate; Colorectal; Endometrial Carcinoma; Cervical Carcinoma; Testicular Cancer; Thyroid Cancer; Small Cell Lung Carcinoma; Mesothelioma; Breast Carcinoma; Esophageal Carcinoma; Gastric Cancer; Pancreatic Carcinoma; Neuroendocrine Cancer; Liver Cancer; Gallbladder Cancer; Biliary Tract Cancer; Anal Carcinoma; Bone Sarcomas; Soft Tissue Sarcomas; Carcinoma of Unknown Origin, Primary
Intervention: Biological: PSMA/PRAME
More Information
Intervention: Biological: PSMA/PRAME
More Information
